Daiichi Sankyo Co. Ltd.’s HER2-directed antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been approved in Japan, for the treatment of patients with HER2-positive unresectable or recurrent metastatic breast cancer after prior chemotherapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?